Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Blunt

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Frontiers in Oncology|December 20, 2021
Selinexor Enhances NK Cell Activation Against Malignant B Cells <i>via</i> Downregulation of HLA-EJack G Fisher, Christopher J Walker, Amber Dp Doyle, et al.
Clinical and Experimental Immunology|January 13, 2026
CD40L and IL-4 Lymph Node-Associated Signals Protect B Cells from Rituximab-Induced ADCC via KIR and NKG2ALara V Graham, Russell B Foxall, Margaret Ashton-Key, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptorsPauline Rettman, Matthew D Blunt, Rebecca J Fulton, et al.
Leukemia|May 11, 2023
Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLLDean Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2022
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer ActivityMatthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, et al.
Leukemia|August 1, 2023
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expressionJack G Fisher, Amber D P Doyle, Lara V Graham, et al.
Frontiers in Oncology|September 17, 2024
KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodiesLara V Graham, Jack G Fisher, Amber D P Doyle, et al.
Science Advances|August 23, 2024
The nuclear export protein XPO1 provides a peptide ligand for natural killer cellsMatthew D Blunt, Hayden Fisher, Ralf B Schittenhelm, et al.
Blood|March 23, 2016
IL-4 enhances expression and function of surface IgM in CLL cellsMaria M Aguilar-Hernandez, Matthew D Blunt, Rachel Dobson, et al.
Blood|May 10, 2015
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse modelMatthew D Blunt, Matthew J Carter, Marta Larrayoz, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|December 20, 2021
Selinexor Enhances NK Cell Activation Against Malignant B Cells <i>via</i> Downregulation of HLA-EJack G Fisher, Christopher J Walker, Amber Dp Doyle, et al.
Clinical and Experimental Immunology|January 13, 2026
CD40L and IL-4 Lymph Node-Associated Signals Protect B Cells from Rituximab-Induced ADCC via KIR and NKG2ALara V Graham, Russell B Foxall, Margaret Ashton-Key, et al.
Journal for Immunotherapy of Cancer|May 21, 2021
Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptorsPauline Rettman, Matthew D Blunt, Rebecca J Fulton, et al.
Leukemia|May 11, 2023
Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLLDean Bryant, Lindsay Smith, Karly Rai Rogers-Broadway, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 2022
KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer ActivityMatthew D Blunt, Andres Vallejo Pulido, Jack G Fisher, et al.
Leukemia|August 1, 2023
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expressionJack G Fisher, Amber D P Doyle, Lara V Graham, et al.
Frontiers in Oncology|September 17, 2024
KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodiesLara V Graham, Jack G Fisher, Amber D P Doyle, et al.
Science Advances|August 23, 2024
The nuclear export protein XPO1 provides a peptide ligand for natural killer cellsMatthew D Blunt, Hayden Fisher, Ralf B Schittenhelm, et al.
Blood|March 23, 2016
IL-4 enhances expression and function of surface IgM in CLL cellsMaria M Aguilar-Hernandez, Matthew D Blunt, Rachel Dobson, et al.
Blood|May 10, 2015
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse modelMatthew D Blunt, Matthew J Carter, Marta Larrayoz, et al.
Pageof 4